News

Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

LP-284 Exhibits Preclinical Efficacy in DDR-Deficient MCL

Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise

BPT20: Artificial Intelligence in Drug Discovery Productivity Index

Powering Cancer Drug Discovery and Development Using the Artificial Intelligence and Machine Learning Platform RADR®

LP-284 Shows Preclinical Activity in ATM-Mutated MCL

Lantern Pharma releases positive Preclinical Data on Efficacy of LP-284 for Mantle Cell Lymphoma

Highs and lows of drug repurposing

Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer

Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate

Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA

Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC

Lantern Pharma: transforming oncology drug development with AI

Nearly 300 Novel Agents Currently in Development for Rare Cancers

This Pharma Company Is Using Machine Learning And AI To Attempt To Transform Oncology Drug Development Processes

Lantern Pharma is Using Artificial Intelligence to Develop Oncology Treatments

Episode 703: Panna Sharma on Leveraging Artificial Intelligence To Rescue and Develop Cancer Therapies

Action & Ambition Podcast

Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT)

Lantern Pharma Collaborating With Danish Cancer Research Center on Drugs for NER-Deficient Tumors

Lantern Pharma and NCI expand oncology partnership

Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates

Lantern Pharma (LTRN) Reports Positive Efficacy Data of LP-284 in Hematologic Cancers

What is the Real Cost of Developing Medicine?

Healthcare Americana Podcast

Cost of Care: Defanged drug pricing reform means less of a bite for Big Pharma

The Local Oncology Innovator ‘Smashing’ Drug Development Timelines

Why we are on the cusp of a golden age of medicine

The AI Pharmacist: How Artificial Intelligence Can Accelerate Drug Development

Slice of Healthcare Podcast #192 – Panna Sharma, CEO & President at Lantern Pharma

How Technologies Like AI and Machine Learning Can Help With the Development of Medicine

TradeTalks Video Broadcasts - With Jill Malandrino

BioBoss Podcast #39 - Panna Sharma, CEO of Lantern Pharma

Biotech is sprouting into Dallas-Fort Worth’s next big thing, based on seeds planted decades ago

Join our team and help transform the cancer drug development process, cost and timeline!

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

Lantern Pharma CEO Shares His Four Secrets to Turning a Startup into an IPO

Benzinga's Power Hour Show

How AI Is Expediting Medicine Development

Allarity Therapeutics, Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

Dallas region sees growing traction around the life sciences amid IPOs, fundings

Preclinical Data on New Pancreatic Cancer Drug Shines with over 90% Efficacy

Midday Hot Stocks: SPCE falls as Bezos flies; HAL, UBS rise on earnings; LTRN gets strong pre-clinical data

How AI Is Transforming the Healthcare Landscape & Accelerating the Development of Medicine

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing

New Lantern Manuscript: The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

Lantern ($LTRN) Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with

A machine learning‐based gene signature of response to the novel alkylating agent LP‐184 distinguishes its potential tumor indications

Technology Is Rapidly Changing Cancer Care

AI offers promise but faces barriers in drug development

Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development

Episode 68: Rocking Garage Biotech

What going public means for Lantern Pharma

Lantern Pharma, Fox Chase Partner on Pancreatic Cancer Drug, Search for Predictive Gene Signature